137419-24-0

Basic information

• Product Name: CHEMBRDG-BB 4011973
• Synonyms: CHEMBRDG-BB 4011973;TERT-BUTYL 1'H-SPIRO[INDENE-1,4'-PIPERIDINE]-1'-CARBOXYLATE;tert-Butyl spiro[1H-indene-1,4'-piperidine]-1'-carboxylate;tert-butyl spiro[indene-1,4'-piperidine]-1'-carboxylate;tert-butyl 1'H-spiro[indene-1,4'-piperidine]-1'-carboxylate(SALTDATA: FREE);1'-BOC-SPIRO(INDENE-1,4'-PIPERIDINE);Spiro[1H-indene-1,4'-piperidine]-1'-carboxylic acid 1,1-diMethyl ethyl ester;1'-(tert-butyloxycarbonyl)spiro
• CAS NO: 137419-24-0
• Molecular Formula: C₁₈H₂₃NO₂
• Molecular Weight: 285.38
• Mol File: 137419-24-0.mol

Chemical Properties

• Boiling Point: 406.2±45.0 °C(Predicted)
• Appearance: /
• Density: 1.13±0.1 g/cm3(Predicted)
• PKA: -0.79±0.20(Predicted)
• CAS DataBase Reference: CHEMBRDG-BB 4011973(CAS DataBase Reference)
• NIST Chemistry Reference: CHEMBRDG-BB 4011973(137419-24-0)
• EPA Substance Registry System: CHEMBRDG-BB 4011973(137419-24-0)

Safety Data

• Hazardous Substances Data: 137419-24-0(Hazardous Substances Data)

Usage

Uses

Used in Agricultural Industry:
CHEMBRDG-BB 4011973 is used as an insecticide and acaricide for controlling a variety of insect and mite pests that threaten crop yields. Its mode of action involves the inhibition of chitin synthesis, which is essential for the formation of the exoskeleton in insects. This disruption leads to a failure in the growth and development of the pests, ultimately resulting in their death and providing protection to crops from damage.
The effectiveness of CHEMBRDG-BB 4011973 in pest control makes it a valuable asset in the agricultural industry, ensuring the preservation of crops and contributing to increased agricultural productivity.

Upstream product

• 118753-70-1 N-(tert-butyloxycarbonyl)bis(2-chloroethyl)amine 
• 95-13-6 1-indene 
• 4039-32-1 lithium hexamethyldisilazane 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 241819-85-2 tert-butyl 2-oxo-2,3-dihydrospiro[indene-1,4'-piperidine]-1'-carboxylate 
• 180465-55-8 spiro[1H-indene-1,4'-piperidin]-3(2H)-one 
• 791042-20-1 C₁₃H₁₇NO₂ 
• 185525-95-5 C₂₃H₂₆N₂O₃ 
• 185525-94-4 C₂₈H₃₄N₂O₅ 
• 185526-08-3 C₃₃H₄₃N₃O₅ 
• 185525-96-6 C₃₂H₄₁N₃O₆ 
• 96651-85-3 2,3-dihydrospiro[1H-indene-1,4'-piperidine] hydrochloride 
• 159634-59-0 2,3-dihydro-3-oxo-spiro[1H-indene-1,4'-piperidine]-1'-carboxylic acid 1,1-dimethylethyl ester 
• 185525-42-2 tert-butyl 3-hydroxy-2,3-dihydrospiro[indene-1,4’-piperidine]-1‘-carboxylate 
• 189149-23-3 tert-butyl 2-hydroxy-2,3-dihydrospiro[indene-1,4’-piperidine]-1‘-carboxylate 

Relevant articles and documents

Discovery and characterization of a potent and selective antagonist of melanin-concentrating hormone receptor 2

A series of spiropiperidine carbazoles were synthesized and evaluated as MCHR2 antagonists using a FLIPR assay. The pharmacokinetic properties of selected compounds have also been studied. This effort led to the discovery of potent and specific MCHR2 antagonists. Compound 38 demonstrated good pharmacokinetic properties across rat, beagle dog and rhesus monkey and had a favorable selectivity profile against a number of other receptors. These MCHR2 antagonists are considered appropriate tool compounds for study of the function of MCHR2 in vivo.

Novel heterocyclic derivative capable of being used as SHP2 inhibitor

The invention relates to a novel heterocyclic derivative capable of being used as an SHP2 inhibitor, specifically relates to a compound shown by a formula I or pharmaceutically acceptable salts thereof, further relates to a use of the compound shown by the formula I or the pharmaceutically acceptable salts thereof and a pharmaceutical composition thereof in drug preparation, and particularly relates to a use in preparation of drugs for treatment, inhibition or prevention of diseases or discomforts mediated by SHP2 activity.

A class of GPR40 agonist compounds with amide structure, and uses thereof

The present invention relates to a class of amide compounds with a novel structure, and a pharmaceutical composition thereof, wherein the structure of the amide compound is represented by a general formula (I). According to the present invention, the amide compound (I) can regulate GPR40 activity, and can be used for GPR40 activity related diseases such as diabetes and metabolic syndrome. The formula I is defined in the specification.

NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Provided are 2-(piperidin-1-yl)pyrimidin-4(3H)-ones or pharmaceutically acceptable salts thereof, each characterized by having a 1,8-diazaspiro[4.5]deca-3-ene, 1-oxa-8-azaspiro[4.5]deca-3-ene, 2,8-diazaspiro[4.5]deca-3-ene, 2-oxa-8-azaspiro[4.5]deca-3-ene, 2,9-diazaspiro[5.5]undeca-3-ene, 1-oxa-9-azaspiro[5.5]undeca-3-ene, 1,9-diazaspiro[5.5]undeca-4-ene, or 3,9-diazaspiro[5.5]undeca-1-ene structure represented by the following general formula (1):

Compound as potassium channel modulator

The invention relates to a compound as a potassium channel modulator, which is a compound of a formula (I) or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof is effective for curing and preventing diseases and symptoms influenced by the activity of potassium ion channels.

NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS

This invention relates to certain novel pyrazine derivatives (Formula I) as SHP2 inhibitors which is shown as formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention is directed to fused heterocyclic group derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder.

Whole cell screen based identification of spiropiperidines with potent antitubercular properties

Abstract Whole cell based screens to identify hits against Mycobacterium tuberculosis (Mtb), carried out under replicating and non-replicating (NRP) conditions, resulted in the identification of multiple, novel but structurally related spiropiperidines with potent antitubercular properties. These compounds could be further classified into three classes namely 3-(3-aryl-1,2,4-oxadiazol-5-yl)-1′-alkylspiro[indene-1,4′-piperidine] (abbr. spiroindenes), 4-(3-aryl-1,2,4-oxadiazol-5-yl)-1′-alkylspiro[chromene-2,4′-piperidine] (abbr. spirochromenes) and 1′-benzylspiro[indole-1,4′-piperidin]-2(1H)-one (abbr. spiroindolones). Spiroindenes showed ≥4 log10 kill (at 2-12 μM) on replicating Mtb, but were moderately active under non replicating conditions. Whole genome sequencing efforts of spiroindene resistant mutants resulted in the identification of I292L mutation in MmpL3 (Mycobacterial membrane protein Large), required for the assembly of mycolic acid into the cell wall core of Mtb. MIC modulation studies demonstrated that the mutants were cross-resistant to spirochromenes but not to spiroindolones. This Letter describes lead identification efforts to improve potency while reducing the lipophilicity and hERG liabilities of spiroindenes. Additionally, as deduced from the SAR studies, we provide insights regarding the new chemical opportunities that the spiroindolones can offer to the TB drug discovery initiatives.

SUBSTITUTED HETEROCYCLIC DERIVATIVES AS GPR AGONISTS AND USES THEREOF

The present invention generally relates to substituted heterocyclic derivatives (the compounds of Formula (I)), processes for their preparation, pharmaceutical compositions containing said compounds, their use as G-protein coupled receptor (GPR) agonists, particularly as GPR40 agonists and methods of using these compounds in the treatment of GPR40 mediated diseases or conditions such as Type 2 diabetes, obesity, dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

NOVEL SPIRO COMPOUND AND MEDICINE COMPRISING THE SAME

It is to provide a novel compound useful for preventing and/or treating diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome. A spiro compound represented by the following general for

ANTAGONISTS OF PGD2 RECEPTORS

Described herein are compounds and pharmaceutical compositions containing such compounds that modulate the PGD2 activated chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2). Also described herein are methods of using such CRTH2 modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2 mediated conditions or diseases.